Active ingredients | | Date of last message | Type of reason | AM designation |
Lidocaine hydrochloride monohydrate | Change notification | 17.10.2025 | Other | Xylocaine Gel 2% |
Estriol | Initial report | 17.10.2025 | Other | Ovestin 1 mg cream |
Mivacurium chloride | Initial report | 17.10.2025 | Other | Mivacron 10 mg |
Lidocaine | Initial report | 17.10.2025 | Other | XYLOCAIN PUMP SPRAY dental |
Salbutamol sulfate | Change notification | 17.10.2025 | Other | Sultanol forte ready-to-use inhalation solution |
Levothyroxine sodium | Initial report | 17.10.2025 | Production problem | L-thyroxine Henning 50 |
Levothyroxine sodium | Initial report | 17.10.2025 | Production problem | L-thyroxine Henning 125 |
Levothyroxine sodium | Initial report | 17.10.2025 | Production problem | L-Thyroxine Henning 75 |
Gentamicin sulfate | Initial report | 17.10.2025 | Production problem | Gentamicin-POS |
Phenylephrine hydrochloride | Change notification | 17.10.2025 | Production problem | Neosynephrine-POS 5% |
Fampridine | Change notification | 17.10.2025 | Other | FAMPRIDIN BASICS 10 mg prolonged-release tablets |
Atorvastatin calcium trihydrate (Ph.Eur.) | Initial report | 17.10.2025 | Other | ATORVASTATIN BASICS 80 mg film-coated tablets |
Olanzapine embonate monohydrate | Initial report | 17.10.2025 | Other | ZYPADHERA 405 mg powder and solvent for the preparation of a prolonged-release injection suspension – OP(931mg+3ml) |
Candesartan cilexetil | Initial report | 17.10.2025 | Other | ATACAND 16 mg |
Olanzapine embonate monohydrate | Change notification | 17.10.2025 | Production problem | ZYPADHERA 210 mg powder and solvent for the preparation of a prolonged-release suspension for injection – OP(483mg+3ml) |
Methyldopa (Ph.Eur.) | Initial report | 17.10.2025 | Production problem | Presinol 250 |
Insulin detemir | Initial report | 17.10.2025 | Other | Levemir 100 IU solution for injection in pre-filled pen – OP(10x3ml)(FlexPen) |
Insulin detemir | Initial report | 17.10.2025 | Other | Levemir 100 IU injection solution in cartridge – OP(10x3ml) |
Betamethasone dipropionate (Ph.Eur.); gentamicin sulfate | Initial report | 16.10.2025 | Other | Diprogenta |
Posaconazole | Initial report | 16.10.2025 | Other | Posaconazole HEXAL 40 mg/ml oral suspension |
Oxytocin | Initial report | 16.10.2025 | Production problem | Oxytocin 3 IU Hexal |
Human insulin (with manufacturing details) | Initial report | 16.10.2025 | Other | Berlinsulin H Basal 3 ml pen |
Insulin aspart | Change notification | 16.10.2025 | Other | NovoMix 30 FlexPen 100 IU/ml injection suspension in pre-filled syringe – OP(10x3ml) |
Human insulin (with manufacturing details) | Initial report | 15.10.2025 | Other | Berlinsulin H Normal 3 ml pen |
Methylprednisolone | Initial report | 15.10.2025 | Other | Methylprednisolone 4mg JENAPHARM |
Azithromycin dihydrate | Change notification | 15.10.2025 | Other | Azithromycin AL 250 mg film-coated tablets |
Vancomycin hydrochloride | Change notification | 15.10.2025 | Production problem | Vancomycin Lyomark 500 mg |
Vancomycin hydrochloride | Change notification | 15.10.2025 | Production problem | Vancomycin Lyomark 1000 mg powder for concentrate for solution for infusion or oral solution |
Posaconazole | Initial report | 15.10.2025 | Other | Posaconazole AL 40 mg/ml oral suspension |
Methylphenidate hydrochloride | Initial report | 15.10.2025 | Other | Metiphenal 10 mg modified-release hard capsules |
Folic acid hydrate (with information on water content (1:x)) | Initial report | 15.10.2025 | Other | Folic acid AL 5 mg tablets |
Acitretin | Initial report | 15.10.2025 | Other | Acicutan 25 mg hard capsules |
Fusidic acid (Ph.Eur.) | Initial report | 15.10.2025 | Other | Fusicutan ointment |
Oxazepam | Initial report | 15.10.2025 | Other | Durazepam 50 mg forte |
Oxycodone hydrochloride (Ph.Eur.) | Initial report | 14.10.2025 | Production problem | Oxygesic Dispersa acute 5 mg |
Oxycodone hydrochloride (Ph.Eur.) | Initial report | 14.10.2025 | Production problem | Oxygesic Dispersa acute 10 mg |
Oxycodone hydrochloride | Change notification | 14.10.2025 | Other | OXYGESIC 10 mg |
Arsenic(III) oxide | Initial report | 14.10.2025 | Other | TRISENOX 2 mg/ml concentrate for solution for infusion |
Granisetron hydrochloride | Initial report | 14.10.2025 | Other | Kevatril 3 mg/3 ml solution for injection |
Carboplatin | Initial report | 14.10.2025 | Other | Carboplatin Kabi 10 mg/ml concentrate for solution for infusion |
Dexketoprofen trometamol | Initial report | 14.10.2025 | Production problem | Sympal inject 50 mg injection/infusion solution |
Tolterodine tartrate | Initial report | 14.10.2025 | Other | Detrusitol 2 mg film-coated tablets |
Doxepin hydrochloride (Ph.Eur.) | Initial report | 14.10.2025 | Other | Doxepin-ratiopharm 50 mg film-coated tablets |
Doxepin hydrochloride (Ph.Eur.) | Initial report | 14.10.2025 | Other | Doxepin-ratiopharm 25 mg film-coated tablets |
Thiamazole | Initial report | 13.10.2025 | Other | Thiamazole 5 mg Henning |
Iron(III) sodium D-gluconate hydroxide oxide complex (approx. 2:1:1:x:y) | Change notification | 13.10.2025 | Other | Ferrlecit 62.5 mg |
Iron(III) sodium D-gluconate hydroxide oxide complex (approx. 2:1:1:x:y) | Change notification | 13.10.2025 | Other | Ferrlecit 40 mg |
Cisatracurium besylate | Change notification | 13.10.2025 | Other | Nimbex 10 mg |
Zolbetuximab | Change notification | 13.10.2025 | Other | Vyloy |
Paliperidone palmitate | Initial report | 13.10.2025 | Other | XEPLION 50 mg prolonged-release suspension for injection – OP1ml |